[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 7 days · First seen · Last updated

Twist Bioscience and Eli Lilly AI partnership

Overview

Twist Bioscience experienced a significant increase in stock value following the announcement of a partnership with Eli Lilly. The collaboration involves Twist Bioscience providing antibody characterization data services for Lilly TuneLab, an advanced drug discovery initiative that utilizes artificial intelligence and machine learning.

As the partnership progressed, Twist Bioscience shares reached a 52-week high of $184.03. The company intends to use experimental data from the collaboration to train its AbLab antibody developability prediction model. Following the announcement, analysts raised price targets for the company, citing growth potential in AI-driven drug discovery. While the company has set a long-term revenue goal of $1 billion for fiscal year 2031, recent quarterly reports indicated a net loss of $35.05 million.

Entities

Emily Leproust · Eli Lilly · Twist Bioscience Corporation · Twist Bioscience

Timeline

  1. [BUSINESS] 2 sources
    Twist Bioscience shares surge on Eli Lilly AI partnership

    Twist Bioscience shares hit a 52-week high following a new AI drug discovery partnership with Eli Lilly and a price target hike from Leerink, despite recent quarterly losses and a minor CEO stock sale.

  2. [BUSINESS] 2 sources
    Twist Bioscience stock rises following Eli Lilly partnership

    Twist Bioscience shares rose over 31% this week after announcing a partnership with Eli Lilly to provide antibody characterization data services for the AI-driven Lilly TuneLab drug discovery initiative.

Sources

stocknews.com · theascent.com · tokenpost.kr